Objective: Pediatric meningioma is a rare diagnosis. This retrospective review seeks to elucidate pertinent characteristics of pediatric patients presenting with meningioma. Methods: The Seattle Children’s Hospital and Regional Medical Center brain tumor database was surveyed from 1940 through 2004. Twenty patients were identified. Results: The median age of the 20 patients was 13 years. Five patients had radiation-induced meningiomas. Five patients had neurofibromatosis type 2. Ten patients had spontaneously arising meningiomas, 2 of which were malignant. Conclusion: Patients with spontaneously arising meningiomas were younger than those with identified risk factors. There was no recurrence in patients with radiation-induced meningiomas. The only death occurred in a patient with a malignant meningioma.

1.
Germano IM, Edwards MS, Davis RL, Schiffer D: Intracranial meningiomas of the first two decades of life. J Neurosurg 1994;80:447–453.
2.
Baumgartner JE, Sorenson JM: Meningioma in the pediatric population. J Neurooncol 1996;29:223–228.
3.
Cushing H, Eisenhardt L: Meningiomas, Their Classification, Regional Behaviour, Life History, and Surgical end Results. Springfield, Charles C Thomas, 1938, pp 56–73.
4.
Ferrante L, Acqui M, Artico M, Mastronardi L, Rocchi G, Fortuna A: Cerebral meningiomas in children. Childs Nerv Syst 1989;5:83–86.
5.
Rochat P, Johannesen HH, Gjerris F: Long-term follow-up of children with meningiomas in Denmark: 1935 to 1984. J Neurosurg 2004;100:179–182.
6.
Modan B, Baidatz MH, Mart H, Steinitz R, Levin SG: Radiation-induced head and neck tumors. Lancet 1974;1:277–279.
7.
Erdincler P, Lena G, Sarioglu AC, Kuday C, Choux M: Intracranial meningiomas in children: review of 29 cases. Surg Neurol 1998;49:136–141.
8.
Perry A, Dehner LP: Meningeal tumors of childhood and infancy: an update and literature review. Brain Pathol 2003;13:386–408.
9.
Perry A, Giannini C, Raghavan R, Scheithauer BW, Banerjee R, Margraf L, Bowers DC, Lytle RA, Newsham IF, Gutmann DH: Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathological study of 53 cases. J Neuropathol Exp Neurol 2001;60:994–1003.
10.
Sandberg DI, Edgar MA, Resch L, Rutka JT, Becker LE, Souweidane MM: MIB-1 staining index of pediatric meningiomas. Neurosurgery 2001;48:590–597.
11.
Amirjamshidi A, Mehrazin M, Abbassioun K: Meningiomas of the central nervous system occurring below the age of 17: report of 24 cases not associated with neurofibromatosis and review of literature. Childs Nerv Syst 2000;16:406–416.
12.
Merten DF, Gooding CA, Newton TH, Malamud N: Meningiomas of childhood and adolescence. J Pediatr 1974;84:696–700.
13.
Sano K, Wakai S, Ochial C, Takakura K: Characteristics of intracranial meningiomas in childhood. Childs Brain 1981;8:98–106.
14.
Al-Mefty O, Topsakal C, Pravdenkova S, Sawyer JR, Harrison MJ: Radiation-induced meningiomas: clinical, pathological, cytokinetic and cytogenetic characteristics. J Neurosurg 2004;100:1002–1013.
15.
Sadetzki S, Flint-Richter P, Ben-Tal T, Nass D: Radiation-induced meningioma: a descriptive study of 253 cases. J Neurosurg 2002;97:1078–1082.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.